论文部分内容阅读
目的 分析探讨尿激酶静脉溶栓治疗急性脑梗死的疗效。方法 对 1 999～ 2 0 0 3年发病 72h内经临床诊断分析和头颅CT确诊为急性脑硬死患者首次发病 82例住院病例 ,治疗组 4 8例运用静脉注射尿激酶溶栓治疗 1～ 3次 ,通过观察患者临床神经功能缺损程度评分及用临床疗效评定标准进行治疗前后判断分析 ,同时检测血浆中纤维蛋白原含量、肝功能和肾功能。结果 治疗组神经功能缺损评分有显著进步 ,血浆纤维蛋白原含量在用药后降低 ,临床治愈好转率 91 6 7% ,肝肾功能无影响 ,未出现活动性出血 ,未发生过敏反应。结论 尿激酶可安全有效地降低纤维蛋白原含量 ,是有效地治疗急性脑梗死的疗效较好的药物。
Objective To investigate the curative effect of intravenous thrombolytic therapy of urokinase on acute cerebral infarction. Methods A total of 82 inpatients with acute cerebral edema were diagnosed by clinical diagnosis and cranial CT within 72 hours after onset of disease from 1999 to 2003. Forty-eight patients in the treatment group received intravenous urokinase thrombolysis 1 to 3 times , By observing the clinical neurological deficit score and using clinical efficacy evaluation criteria before and after treatment to determine the analysis, at the same time detect plasma fibrinogen content, liver function and renal function. Results The score of neurological deficit in the treatment group was significantly improved. The content of fibrinogen in the treatment group decreased after treatment. The improvement rate of clinical cure was 91.67%. No effect of liver and kidney function, no active bleeding and no allergic reaction occurred. Conclusions Urokinase can reduce fibrinogen safely and effectively, which is an effective drug for the effective treatment of acute cerebral infarction.